Overview
Publication
EClinicalMedicine. 2020 Apr; 21(NA):100303.
PubMed ID: 32280940
Title
Safety and tolerability of injectable Rilpivirine LA in HPTN 076: A phase 2 HIV pre-exposure prophylaxis study in women
Authors
Bekker LG, Li S, Pathak S, Tolley EE, Marzinke MA, Justman JE, Mgodi NM, Chirenje M, Swaminathan S, Adeyeye A, Farrior J, Hendrix CW, Piwowar-Manning E, Richardson P, Eshelman SH, Redinger H, Williams P, Sista ND, HPTN 076 Study Team
Abstract
Daily oral TDF/FTC is protective against HIV infection when used for pre-exposure prophylaxis (PrEP). However, daily adherence to oral PrEP is difficult for many; therefore, finding alternative PrEP strategies remains a priority. HPTN 076 evaluated the long-acting injectable form of rilpivirine (RPV), known as RPV LA for safety, pharmacokinetics and acceptability.
With the publicly available data in the CAVD DataSpace we can Learn about studies, products, assays, antibodies, and publications, Find subjects with common characteristics, Plot assay results across studies and years of research, and Compare monoclonal antibodies and their neutralization curves. Data are also accessible via DataSpaceR, our R API.
Sign in to see full information about this publication and to download study data when available.
Related Studies
No related studies